

CRO Communiqué
Keeping you informed about CRO progress
September 2011

Top Enrolling Physicians for August 2011

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Carlson	18	4.8	2.5	7.3
Dr. Bonebrake	4	4	0.5	4.5
Dr. Kent	1	1	0.5	1.5
Dr. Goodwin	1	1.3	0	1.3
Dr. Nanney	1	1.1	0.1	1.2
Dr. Williams	1	1.1	0	1.1
Dr. Ellis	1	1	0	1
Dr. Holden	1	1	0	1
August Totals	28	15.3	3.6	18.9

WOW! Great job! Enrollments to treatment trials really picked up this month resulting in 15.3 treatment credits. Three months into our grant year we are 1.3 treatment credits ahead in meeting our projected NCI target credit of 120 for the year. We are 0.4 credits behind in meeting our projected cancer control credits of 60 for the year. Thanks to all our investigators and staff who work hard to place patients on clinical trials.

Study Profile

CTSU ECOG E1609 “A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma” is this month’s study to profile. Only patients with melanoma of a cutaneous origin or unknown primary are eligible for this study. Patients with ocular melanoma or melanoma of mucosal origin are not eligible. Patients must have disease that is completely surgically resected with negative margins and rendered free of disease. Prior adjuvant treatment (chemotherapy, biotherapy or limb perfusion) after the resections makes them ineligible for this trial. Investigators must complete the Ipilimumab Immune Related adverse Events slide show and quiz before enrolling patients.

Steering Committee Meeting on October 3, 2011

Mark your calendars for Monday, October 3, 2011 for the next CRO Steering Committee meeting. Ravi Vij from Washington University School of Medicine in St. Louis will be with us to speak on multiple myeloma. Dr. Vij’s professional focus has been hematological malignancies and the development of new treatments. He has initiated or been the principal investigator for 17 clinical trials, invited speaker at over 50 academic medical centers and professional societies and authored over 70 manuscripts and books. The event will be at Flame Restaurant, 314 W. Walnut, Springfield at 6:15pm. Please RSVP to 417-269-4520 by Thursday, September 29, 2011.

CRO Staff Retires

CRO’s research nurse Shirley Gordon was honored at a retirement party on Wednesday, August 24th at St. John’s Whiteside building. Shirley is looking forward to working on her family genealogy and traveling. Shirley worked at St. John’s for thirty-one years. Eleven of those years were spent as a research nurse at CRO. Efforts to hire a new nurse are underway. We hope to have our selection made within the week.

CRO Staff Participate in Pink Glove Event

CRO staff enjoyed a little fun wearing pink boas, pink gloves and dancing to Fireworks by Katy Perry. CRO’s department participated in Hulston’s pink glove video. Hulston Cancer Center is hoping to win a donation to a breast cancer charity and raise breast cancer awareness. To learn more about this national event check out this link www.pinkglovedance.com



Clinical Trials OPEN @ Cox & St. John's in August:

CTSU ECOG E1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma

GOG-0229H A Phase II Evaluation of AZD6244 (NSC #748727, IND #77782) In the Treatment of Recurrent or Persistent Endometrial Carcinoma

GOG-0267 Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube and Peritoneal Cancer

Clinical Trials OPEN @ Cox in August:

NCCTG N08C9 Phase III, Randomized Study of Sulfasalazine versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy (approved at St. John's in July)

Clinical Trials OPEN @ St. John's in August:

GOG-0210 A Molecular Staging Study of Endometrial Cancer

Clinical Trials CLOSED to accrual @ Cox & St. John's in August:

NCCTG N07C2 The Use of Wisconsin Ginseng (panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

NSABP B-41 A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response